The other cohort of CARTITUDE-2, cohort B, enrolled 19 MM patients who had undergone initial therapy with a PI and IMiDs and had disease progression for 12 months or less after frontline therapy but were not yet exposed to CAR T-cell therapy or anti-BCMA antibodies (47, 48). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.